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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
with other types of glomerular disease. 
These results suggest that assessment of 
PLA2R expression in kidney biopsies may 
differentiate patients with MN caused by 
anti-PLA2R antibodies from those with 
secondary forms of MN. See page 797.
The level of galactose-
deficient IgA1 in the 
sera of patients with 
IgA nephropathy is 
associated with disease 
progression
IgA nephropathy (IgAN), the most com-
mon form of glomerulonephritis world-
wide, is characterized by mesangial deposits 
of aberrantly glycosylated IgA. Though pre-
vious studies have shown that serum levels 
of galactose-deficient IgA1 are increased in 
patients with IgAN, it is not known whether 
levels can predict IgAN progression. Zhao 
and colleagues, therefore, measured base-
line serum galactose-deficient IgA1 in 
a prospective cohort of IgAN patients. 
They found that levels of serum galactose-
deficient IgA1 strongly predicted renal 
outcomes. This study is the first to demon-
strate that levels of galactose-deficient IgA1 
predict loss of renal function in IgAN and 
therefore also suggest that galactose-defi-
cient IgA1 may have an important role in 
the pathogenesis of chronic kidney disease 
progression in IgAN. See page 790.
Enhanced expression 
of the M-type 
phospholipase A2 
receptor in glomeruli 
correlates with serum 
receptor antibodies in 
primary membranous 
nephropathy
Recent studies have demonstrated that 
most cases of membranous nephropathy 
(MN), the most common cause of primary 
nephrotic syndrome in Caucasians, are 
caused by antibodies against the M-type 
phospholipase A2 receptor (PLA2R), which 
is present on podocytes. In this issue, Hoxha 
et al. examine whether glomerular PLA2R 
expression is altered in patients with MN. 
They report that patients with MN and 
elevated anti-PLA2R antibody levels have 
higher levels of glomerular PLA2R expres-
sion than patients with MN without detect-
able anti-PLA2R antibodies or patients 
Activation of 
peroxisome proliferator 
-activated receptor-g 
coactivator 1a 
ameliorates mito-
chondrial dysfunction 
and protects podocytes 
from aldosterone-
induced injury
Podocyte injury is an important compo-
nent of the pathogenesis of many kidney 
diseases, and the contribution of mito-
chondrial dysfunction to glomerular 
disease has recently become the focus of 
intensive research. Yuan et al. examined 
the role of peroxisome proliferator-acti-
vated receptor-g (PRAR-g) coactivator 1a 
(PGC-1a), a transcriptional activator of 
PPAR-g and regulator of mitochondrial 
biogenesis, in podocyte cytoprotection. 
They report that PGC-1a expression is 
essential for normal mitochondrial func-
tion in podocytes and can prevent aldos-
terone-induced mitochondrial dysfunction. 
Moreover, the authors demonstrate that 
the histone deacetylase SIRT1 preserves 
mitochondrial function in podocytes 
by deacetylating and thereby activating 
PGC-1a, suggesting that interventions 
to increase PGC-1a may be beneficial in 
preventing or treating glomerular diseases. 
See page 771. 
